Ratings Biocon Limited

Equities

BIOCON

INE376G01013

Delayed NSE India S.E. Other stock markets 02:44:49 2024-05-02 am EDT			5-day change	1st Jan Change
309.8 ^INR	+3.78%		+10.53%	+24.03%

Apr. 30	Natural Biocon (India) CFO Passes Away	MT
Apr. 20	Biocon Limited Receives Approval from the South African Health Products Regulatory Authority for its Vertically Integrated, Complex Drug Product Tacrolimus Capsule 0.5mg, 1mg and 5mg Strengths, in South Africa	CI

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The earnings growth currently anticipated by analysts for the coming years is particularly strong.
For several months, analysts have been revising their EPS estimates roughly upwards.

Weaknesses

The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.5 times its estimated earnings per share for the ongoing year.
The company's enterprise value to sales, at 3.42 times its current sales, is high.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Revenue estimates are regularly revised downwards for the current and coming years.
The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
BIOCON LIMITED	+24.03%	4.27B	A-
VERTEX PHARMACEUTICALS INCORPORATED	-1.17%	104B	B+
REGENERON PHARMACEUTICALS, INC.	+2.87%	97.47B	B+
ARGENX SE	+2.13%	22.25B	B
BIONTECH SE	-14.77%	21.68B	B+
GENMAB A/S	-8.79%	18.2B	A-
WUXI APPTEC CO., LTD.	-39.98%	17.02B	A-
BEIGENE, LTD.	-13.21%	16.36B	B
NEUROCRINE BIOSCIENCES, INC.	+8.55%	14.39B	C+
SAREPTA THERAPEUTICS, INC.	+35.75%	12.37B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes